Core Viewpoint - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. experienced a decline of 5.01% in stock price, closing at 33.75 CNY per share, with a trading volume of 8.12 billion CNY and a turnover rate of 5.19%, resulting in a total market capitalization of 16.125 billion CNY [1] Group 1: Company Overview - Shuyou Shen was established on August 16, 2002, and went public on April 15, 2011. The company is primarily engaged in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue sources for Shuyou Shen include: 59.17% from injectable mouse nerve growth factor (Sutai Sheng), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2: Fund Holdings - Jin Ying Fund has a significant holding in Shuyou Shen, with its Jin Ying Medical Health Stock A (004040) holding 512,100 shares, accounting for 5.14% of the fund's net value, making it the sixth-largest holding [2] - The estimated floating loss for the fund today is approximately 911,500 CNY [2] Group 3: Fund Manager Performance - The fund manager for Jin Ying Medical Health Stock A is Han Guangzhe, who has a tenure of 12 years and 342 days, with a total fund asset size of 1.909 billion CNY. The best fund return during his tenure is 55.35%, while the worst is -56.49% [3] - Co-manager Ouyang Juan has a tenure of 3 years and 27 days, managing assets of 456 million CNY, with a best return of 0.05% and a worst return of -30.47% during her tenure [3]

10月24日，舒泰神跌5.01%，截至发稿，报33.75元/股，成交8.14亿元，换手率5.20%，总市值161.25亿 元。 浙商汇金量化精选混合（006449）基金经理为庞雅菁。 截至发稿，庞雅菁累计任职时间1年270天，现任基金资产总规模1.04亿元，任职期间最佳基金回报 75.8%， 任职期间最差基金回报-3.08%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，浙商证券资管旗下1只基金重仓舒泰神。浙商汇金量化精选混合（006449）二季度持有股数 14.39万股，占基金净值比例为5.18%，位居第二大重仓股。根据测算，今日浮亏损失约25.61万元。 浙商汇金量化精选混合（006449）成立日期2019年3月25日，最新规模1.04亿。今年以来收益62.7%，同 类排名329/8154；近一年收益42.33%，同类排名1111/8025；成立以来收益58.81%。 资料显示，舒泰神(北京)生物制药股份有限公司 ...

Group 1 - The core point of the news is that Shutaishen's stock price increased by 6.33% to 39.33 CNY per share, with a trading volume of 492 million CNY and a turnover rate of 2.77%, resulting in a total market capitalization of 18.791 billion CNY [1] - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shutaishen includes 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under Great Wall Fund holds Shutaishen as a significant investment. The Great Wall Health Life Mixed A Fund (008786) held 328,900 shares in the second quarter, accounting for 3.57% of the fund's net value, ranking as the eighth largest heavy stock [2] - The Great Wall Health Life Mixed A Fund (008786) was established on August 14, 2020, with a latest scale of 343 million CNY. The fund has achieved a return of 30.31% this year, ranking 2759 out of 8160 in its category, and a return of 27.05% over the past year, ranking 2941 out of 8026 [2] - The fund manager of Great Wall Health Life Mixed A is Tan Xiaobing, who has a cumulative tenure of 9 years and 265 days. The total asset scale of the fund is 2.018 billion CNY, with the best fund return during his tenure being 162.51% and the worst being -33.94% [3]

10月16日，舒泰神涨5.49%，截至发稿，报38.25元/股，成交9.85亿元，换手率5.87%，总市值182.75亿 元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 红土创新医疗保健股票（010434）基金经理为廖星昊。 截至发稿，廖星昊累计任职时间3年329天，现任基金资产总规模4.76亿元，任职期间最佳基金回报 44.82%， 任职期间最差基金回报34.28%。 从基金十大重仓股角度 数据显示，红土创新基金旗下1只基金重仓舒泰神。红土创新医疗保健股票（010434）二季度持有股数 73.95万股，占基金净值比 ...

Core Viewpoint - Shuyou Shen's stock price has seen significant fluctuations, with a year-to-date increase of 399.19%, but recent performance shows mixed results, indicating potential volatility in the market [1][2]. Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1]. - The main revenue sources for the company are: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1]. Financial Performance - For the first half of 2025, Shuyou Shen reported operating revenue of 126 million yuan, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.64 million yuan, a year-on-year decrease of 619.70% [2]. - The company has cumulatively distributed 771 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, while the average circulating shares per person decreased by 22.60% to 14,327 shares [2]. - New institutional shareholders include several funds, with notable holdings such as 15.72 million shares by Xingquan Helun Mixed A and 8.81 million shares by Xingquan Commercial Model Mixed A [3]. Market Activity - On October 16, Shuyou Shen's stock rose by 2.01% to 36.99 yuan per share, with a trading volume of 272 million yuan and a turnover rate of 1.66%, resulting in a total market capitalization of 17.673 billion yuan [1]. - The stock has appeared on the daily trading leaderboard seven times this year, with the most recent occurrence on June 9, where it recorded a net buy of -54.65 million yuan [1].

浙商汇金量化精选混合（006449）成立日期2019年3月25日，最新规模1.04亿。今年以来收益59.83%， 同类排名504/8162；近一年收益58.68%，同类排名837/8015；成立以来收益56.01%。 10月14日，舒泰神跌5.01%，截至发稿，报32.45元/股，成交5.38亿元，换手率3.55%，总市值155.04亿 元。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 从基金十大重仓股角度 数据显示，浙商证券资管旗下1只基金重仓舒泰神。浙商汇金量化精选混合（006449）二季度持有股数 14.39万股，占基金净值比例为5.18%，位居第二大重仓股。根据测算，今日浮亏损失约24.61万元。 浙商汇金量化精选混合（006449）基金经理为庞雅菁。 截至发稿，庞雅菁累计任职时间1年260天，现任基金资产总规模1 ...

数据显示，东方阿尔法基金旗下1只基金重仓舒泰神。东方阿尔法健康产业混合发起A（024357）二季 度持有股数1.65万股，占基金净值比例为6.05%，位居第八大重仓股。根据测算，今日浮盈赚取约2.85 万元。 东方阿尔法健康产业混合发起A（024357）成立日期2025年6月12日，最新规模956.35万。成立以来收益 0.29%。 从基金十大重仓股角度 10月13日，舒泰神涨5.21%，截至发稿，报34.92元/股，成交3.34亿元，换手率2.19%，总市值166.84亿 元。 东方阿尔法健康产业混合发起A（024357）基金经理为孟昱。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式 ...

Core Viewpoint - Shuyou Shen's stock price has shown significant volatility, with a year-to-date increase of 364.51%, but recent declines in the short term indicate potential market concerns [1][2]. Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1]. - The main revenue sources are: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1]. Financial Performance - For the first half of 2025, Shuyou Shen reported revenue of 126 million yuan, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.64 million yuan, a decline of 619.70% [2]. - The company has distributed a total of 771 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, with an average of 14,327 circulating shares per person, a decrease of 22.60% [2]. - New institutional shareholders include several funds, with notable holdings such as 15.72 million shares by Xingquan Helun Mixed A and 8.81 million shares by Xingquan Commercial Model Mixed A [3].

Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is located in Beijing Economic and Technological Development Zone, established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1]. Financial Performance - As of September 29, Shuyou Shen's stock price fell by 0.65% to 33.65 CNY per share, with a trading volume of 479 million CNY and a turnover rate of 3.16%. The total market capitalization is 16.077 billion CNY. The stock has experienced a cumulative decline of 6.81% over the past three days [1]. - The main revenue sources for Shuyou Shen are: 59.17% from injectable mouse nerve growth factor (Sutai Shen), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1]. Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under GF Fund holds Shuyou Shen as a significant position. The GF Hong Kong-Shenzhen Medical Mixed A Fund (014114) held 235,700 shares in the second quarter, accounting for 2.86% of the fund's net value, ranking as the tenth largest holding. The estimated floating loss today is approximately 51,900 CNY, with a total floating loss of 579,800 CNY during the three-day decline [2]. - The GF Hong Kong-Shenzhen Medical Mixed A Fund was established on December 29, 2021, with a current scale of 204 million CNY. Year-to-date returns are 76.81%, ranking 223 out of 8,244 in its category; the one-year return is 84.5%, ranking 709 out of 8,080; and since inception, the return is 14.5% [2]. Fund Management - The fund manager of GF Hong Kong-Shenzhen Medical Mixed A Fund is Wu Xingwu, who has been in the position for 10 years and 233 days. The total asset size of the fund is 9.853 billion CNY, with the best fund return during his tenure being 112.41% and the worst being -33.74% [3].

Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with a significant revenue contribution from injectable nerve growth factor (Sutai) at 59.17% and compound polyethylene glycol electrolyte powder at 33.19% [1][2] Stock Performance - As of September 29, Shuyou Shen's stock price decreased by 2.10% to 33.16 CNY per share, with a total market capitalization of 15.843 billion CNY [1] - The stock has seen a year-to-date increase of 347.50%, but has declined by 8.68% over the last five trading days, 38.43% over the last 20 days, and 24.84% over the last 60 days [1] Financial Performance - For the first half of 2025, Shuyou Shen reported a revenue of 126 million CNY, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.636 million CNY, a decline of 619.70% [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, with an average of 14,327 shares per shareholder, down by 22.60% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Institutional Holdings - Notable new institutional shareholders include Xingquan He Run Mixed A, holding 15.721 million shares, and several other funds, indicating a shift in shareholder composition [3]